Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to improve life after gynecologic cancer

NCT ID NCT06553612

Knowledge-focused Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a special hospital visit with a team of experts can help women who finished treatment for ovarian or endometrial cancer get more of the supportive care they need. About 268 women in remission will be split into groups: some get the extra hospital assessment and a nurse coordinator, others get standard follow-up. The goal is to see if this approach leads to better use of services like nutrition, physical therapy, or counseling, and ultimately improves quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 268 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient \> 18 years * Patients in remission from first-line treatment of endometrial or ovarian/tumor/peritoneal cancer. * Patient who has completed her initial treatment; patients on maintenance therapy are eligible. * Fluency in French * Patient with access to a telephone line * Patient affiliated to a social security scheme * Signature of informed consent prior to any specific study procedure Exclusion Criteria: * Any associated medical or psychiatric condition that could compromise the patient's ability to participate in the study * Patient with locoregional or metastatic recurrence * Patient deprived of liberty, under guardianship or curatorship * Simultaneous participation in a therapeutic clinical trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer female reproductive organ cancer ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gynecologic cancer Remission

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU

    RECRUITING

    Strasbourg, France

  • CHU, Besançon

    RECRUITING

    Besançon, France

  • CHU, Saint Etienne

    NOT_YET_RECRUITING

    Saint-Etienne, France

  • Centre Jean Perrin

    NOT_YET_RECRUITING

    Clermont-Ferrand, France

  • Centre Léon Bérard

    RECRUITING

    Lyon, France

  • François Baclesse

    RECRUITING

    Caen, France

  • Gustave Roussy

    RECRUITING

    Villejuif, France

  • Hopital Diaconesses Croix Saint-Simon

    RECRUITING

    Paris, France

  • Hopital Europeen George Pompidou

    NOT_YET_RECRUITING

    Paris, France

  • Hopital privé des Côtes d'Armor

    NOT_YET_RECRUITING

    Plérin, France

  • Hôpital COCHIN

    NOT_YET_RECRUITING

    Paris, France

  • Institut Curie

    NOT_YET_RECRUITING

    Paris, France

  • Institut Curie, St Cloud

    RECRUITING

    Saint-Cloud, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.